Monopar Therapeutics
Price & Volume
Stats
See moreOpen | $99.54 |
Previous Close | $104.50 |
Day Range | $98.93-$107.41 |
52W Range | $29.18-$112.25 |
Market Cap | $700M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.03 |
News
See moreYahoo Finance • 14 days ago
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Yahoo Finance • 17 days ago
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
Yahoo Finance • 2 months ago
Monopar's ALXN1840 Shows Significant Copper Reduction In Phase 2 Trial For Wilson Disease
Yahoo Finance • 2 months ago
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
About
CEO | Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. |
CFO | Mr. Quan Anh Vu |
Address | 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 22 |